Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Florida Legislature Passes Bill Proposed by The Florida Allergy, Asthma & Immunology Society to Increase Food-Allergy Safety Measures in Schools
  • USA - English


News provided by

Allergy & Asthma Specialists of North Florida, P.A.

Aug 20, 2013, 06:00 ET

Share this article

Share toX

Share this article

Share toX


The Florida Allergy, Asthma & Immunology Society worked hard to help assure the safety of our school children.

Post this

Jacksonville, FL (PRWEB) August 20, 2013 -- The Florida Allergy, Asthma & Immunology Society, which represents approximately 150 allergists throughout the state of Florida, proposed an amendment to the current legislature pertaining to anaphylaxis in schools. Bill 284, School Emergencies, enables public and private schools to adopt an anaphylaxis protocol to be developed by a licensed physician. School personnel will be trained on how to recognize anaphylaxis, treat an anaphylactic emergency and be trained how to use epinephrine auto-injectors. It also permits schools to maintain a non-student-specific stock of epinephrine auto-injectors for emergency use.

The primary sponsors of the important collaborate amendment were Representative Mike LaRosa and Senator Joe Negron. It was signed by Governor Rick Scott on May 30 and took effect July 1, 2013.

According to Patrick J. DeMarco, MD, FAAAAI, FACAAI, of Allergy & Asthma Specialists of North Florida, "This was a team effort. Passionate allergists of the Florida Allergy, Asthma & Immunology Society worked hard to help assure the safety of our school children." He notes that a number of groups were instrumental in the advancement of the bill, including medical specialty societies, the Florida Medical Association, county medical societies, patient advocacy groups, legislators, school nurses and other school personnel, and, most importantly, the parents of children who have or know someone with potentially life-threatening food allergies. Additionally, two manufacturers of epinephrine auto-injectors, Mylan and Sanofi-Aventis, have agreed to distribute devices to every public and private school in the state. The Florida Allergy, Asthma & Immunology Society and its members agreed to assist in the development of protocols and to train school personnel.

According to the American Academy of Allergy, Asthma & Immunology Society, one in every 13 children, or approximately two children per classroom, have a food allergy. Anaphylaxis is a potentially life-threatening reaction that may occur by accidental ingestion of a food allergen. Immediate administration of epinephrine is the only treatment that has shown to be effective in preventing deaths from anaphylaxis. Epinephrine currently comes in two different auto-injector devices, Epi-pen and Auvi-Q and is very safe in children, with the most common side effect being a transient increase in heart rate. Similar to automated external defibrillators (AEDs), which are available in schools for life-threatening heart disease, these prescription devices are designed for self-administration by non-medical personnel and require minimal training to use.

While the majority of children diagnosed with food allergies are aware of their allergy, 25 percent of epinephrine administrations occurring in school involve children whose risk for allergy was unknown at the time of a reaction. Previous Florida legislation allowed a student to have a prescription auto-injector available at school, but it did not allow schools to keep a “stock” supply of epinephrine for emergency use. Unfortunately, this meant that any child who experienced a first-time anaphylactic reaction at school did not have access to this life-saving treatment. It also placed known food-allergic children at risk if they did not have an epinephrine auto-injector readily available. In fact, this was an unfortunate reality for a 7-year old Virginia student, Ammaria Johnson, who died of a food-induced anaphylactic reaction at school in 2012. She did not have an injectable epinephrine auto-injector at school and the school did not have a non-student-specific stock of epinephrine. Her death may have been prevented if epinephrine was readily available and if school personnel were allowed to administer the medication without fear of liability.

"This amendment represents a major victory for Florida students," said Dr. DeMarco. "It gives our school personnel the training and tools to freely treat anaphylaxis in all school children. Hopefully, Florida school districts, encouraged by physicians and parents, will seize this opportunity to protect all students from life-threatening food allergies."

About Dr. Patrick DeMarco
Dr. DeMarco is board-certified in Allergy & Immunology practicing in Jacksonville, Florida, and is the immediate past president of the Florida Allergy, Asthma & Immunology Society.

For more information, please contact:
Patrick J. DeMarco, MD, FAAAI, FACAAI
Allergy & Asthma Specialists of North Florida
2804 St. Johns Bluff Road South, Suite 202
Jacksonville, Florida 32246
pdemarco(at)jaxallergy(dot)com
904-730-4870
http://www.jaxallergy.com

Dr. Patrick DeMarco, Allergy & Asthma Specialists of North Florida, P.A., http://www.jaxallergy.com, +1 (904)730-4870, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.